聯合化療市場規模、佔有率和成長分析：按藥物、劑量、給藥方法、不孕性別和地區分類 - 產業預測，2024-2031 年

聯合化療市場規模將於2022年達到50.7億美元，從2023年的53.3億美元成長到2031年的79.2億美元，在預測期間（2024-2031年）預計複合年成長率為5.08%。

由於多種因素，聯合化療市場正在經歷顯著成長。癌症發生率的增加、藥物配製技術的進步以及易患癌症的老年人口的增加強調了個人化治療的必要性。然而，市場面臨嚴格的監管標準和與化療製劑相關的安全問題的挑戰，凸顯了監管合規性和病人安全的重要性。同時，充滿希望的機會也正在出現，包括配方技術的進步和精準醫療策略的更多採用。

目錄

介紹

• 這項研究的目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 次要/一級資訊來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 技術分析
• 價格分析
• 價值鏈分析
• 市場生態系統
• Start-Ups分析
• 監管環境
• 創新矩陣
• 重點投資分析
• 關鍵成功因素
• 市場魅力指數
• 競爭程度

聯合化療市場：依藥物分類

• 市場概況
• 細胞毒性藥物
• 荷爾蒙藥物
• 免疫調節劑
• 標靶治療
• 支持治療藥物

聯合化療市場：按劑量

• 市場概況
• 化療
• 非化療藥物

聯合化療市場：按給藥方式

• 市場概況
• 重量式自動混配裝置
• 容積式自動配料裝置

聯合化療市場：不孕性別

• 市場概況
• 已滅菌
• 非無菌

聯合化療市場：依技術分類

• 市場概況
• 機械臂
• 無機械臂

聯合化療市場：按組合類型

• 市場概況
• 藥物成分變化（PIA）
• 目前無法使用的藥品製造 (CUPM)
• 藥物劑量變更 (PDA)

聯合化療市場：依組合藥物類型

• 市場概況
• 藥管
• 等盾臨
• 麥迪米克斯
• 整合
• 其他

聯合化療市場：依應用分類

• 市場概況
• 乳癌
• 血癌
• 攝護腺癌
• 消化道癌症
• 呼吸道/肺癌
• 其他

聯合化療市場規模：按地區

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• Pfizer Inc.（United States）
• Novartis International AG（Switzerland）
• Roche Holding AG（Switzerland）
• Eli Lilly and Company（United States）
• Bristol Myers Squibb Company（United States）
• Merck & Co., Inc.（United States）
• Johnson & Johnson（United States）
• Sanofi SA（France）
• AstraZeneca PLC（United Kingdom）
• Takeda Pharmaceutical Company Limited（Japan）
• AbbVie Inc.（United States）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Amgen Inc.（United States）
• Bayer AG（Germany）
• Gilead Sciences, Inc.（United States）
• Celgene Corporation（United States）
• Biogen Inc.（United States）
• Astellas Pharma Inc.（Japan）
• Daiichi Sankyo Company, Limited（Japan）
• Regeneron Pharmaceuticals, Inc.（United States）

Compounding Chemotherapy Market size was valued at USD 5.07 billion in 2022 and is poised to grow from USD 5.33 billion in 2023 to USD 7.92 billion by 2031, growing at a CAGR of 5.08% in the forecast period (2024-2031).

The compounding chemotherapy market is experiencing substantial growth driven by several factors. These include the increasing incidence of cancer, advancements in pharmaceutical compounding technologies, and a growing elderly population more prone to cancer, emphasizing the need for personalized treatment. However, the market encounters challenges such as stringent regulatory standards and safety issues related to chemotherapy compounding, highlighting the critical importance of adherence to regulations and patient safety. On the other hand, promising opportunities are emerging, including ongoing advancements in compounding technologies and the rising adoption of precision medicine strategies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Compounding Chemotherapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Compounding Chemotherapy Market Segmental Analysis

Global Compounding Chemotherapy Market is segmented based on drug, dose, delivery method, sterility, and region. Based on drug, the market is segmented into cytotoxic drugs, hormonal agents, immunomodulatory agents, targeted therapies, and supportive care drugs. Based on dose, the market is segmented into Chemotherapeutic and Non-Chemotherapeutics. Based on delivery methods, the market is segmented into gravimetric automated compounding devices and volumetric automated compounding devices. Based on sterlity, the market is segmented into Sterile and Non-Sterile. Based on region, the market is segmented into North America, Euorpe, Asia Pacific, Latin America, Middle East & Africa.

Drivers of the Compounding Chemotherapy Market

The move towards personalized medicine is opening substantial opportunities for the combination therapy market. As healthcare providers increasingly recognize the significance of tailored therapeutic approaches, there has been a significant rise in demand for personalized treatments. Combination therapy is uniquely positioned to capitalize on this trend by offering the flexibility to customize treatments based on patient-specific characteristics. By streamlining custom formulations, these products address a shifting paradigm in chemotherapy healthcare, where personalized approaches are increasingly recognized as crucial for achieving successful outcomes.

Restraints in the Compounding Chemotherapy Market

One of the primary obstacles in the market arises from the absence of standardized practices and formulations. Variations in pharmaceutical compositions and formulations pose challenges regarding the stability and reliability of combination therapeutics. These differences can affect the potency and stability of drugs, potentially resulting in inconsistent clinical outcomes for patients. The lack of a standardized protocol for drug combinations presents a barrier for healthcare professionals, complicating their ability to compare and assess various drug combinations effectively.

Market Trends of the Compounding Chemotherapy Market

Pharmacogenomics explores how an individual's genetic profile influences their response to medications, examining intricate interactions between genetic variations and drug effects. Understanding pharmacokinetics empowers healthcare providers to refine treatment approaches, aiming to enhance outcomes for each patient. Incorporating pharmacotherapeutic insights is especially beneficial in developing combination therapies, allowing drugs to be personalized based on a patient's specific genotype. This personalized approach enables healthcare providers to optimize treatment effectiveness while minimizing the potential for adverse effects.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Start-up Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Market Attractive Index
• Degree of Competition

Global Compounding Chemotherapy Market by Drug

• Market Overview
• Cytotoxic drugs
• Hormonal agents
• Immunomodulatory agents
• Targeted therapies
• Supportive care drugs

Global Compounding Chemotherapy Market by Dose

• Market Overview
• Chemotherapeutic
• Non-Chemotherapeutics

Global Compounding Chemotherapy Market by Delivery Method

• Market Overview
• Gravimetric Automated Compounding Devices
• Volumetric Automated Compounding Devices

Global Compounding Chemotherapy Market by Sterility

• Market Overview
• Sterile
• Non-Sterile

Global Compounding Chemotherapy Market by Technology

• Market Overview
• Robotic Arms
• Without Robotic Arms

Global Compounding Chemotherapy Market by Compounding Type

• Market Overview
• Pharmaceutical Ingredient Alteration (PIA)
• Currently Unavailable Pharmaceutical Manufacturing (CUPM)
• Pharmaceutical Dosage Alteration (PDA)

Global Compounding Chemotherapy Market by Compounder Type

• Market Overview
• Pharmoduct,
• Equashield Pro
• Medimix
• Integra
• Others

Global Compounding Chemotherapy Market by Application

• Market Overview
• Breast Cancer
• Blood Cancer
• Prostate Cancer
• Gastrointestinal Cancer
• Respiratory/Lung Cancer
• Others

Global Compounding Chemotherapy Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments